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Dear Editor,
Acute lymphoblastic leukemia (ALL) is a clinically and
biologically heterogeneous disease recurrently affected by
chromosomal aberrations, including translocations,
amplifications, and aneuploidies1. These aberrations have
important implications for the diagnosis, sub-classifica-
tion, prognosis and, overall, for making appropriate
therapeutic decisions. The reciprocal translocation
t(12;21)(p13;q22)[ETV6/RUNX1] is the most frequent
chromosomal rearrangement in pediatric B-cell acute
lymphoblastic leukemia (B-ALL) with an incidence of
~25%2. This rearrangement, as well as high hyperdiploidy,
is associated with a favorable outcome under current
treatment protocols, but up to 20% of ETV6-RUNX1-
positive pediatric B-ALL patients experience a late disease
relapse1,3.
Long non-coding RNAs (lncRNAs) are dysregulated in
cancer, leading to oncogenic or tumor-suppressive activ-
ities, as we reviewed4. Recent microarray studies have
assessed the differential expression of lncRNAs among
different subtypes of pediatric B-ALL5,6. However, the few
studies so far on lncRNA expression and pediatric B-ALL
patient survival were inconclusive or limited due to con-
founding variables or lack of statistical significance6,7.
In this work, we performed a comparative study of the
lncRNA profiles of pediatric B-ALL patients with and
without the ETV6-RUNX1 gene fusion and we combined
our differential expression results with clinical informa-
tion and external data. We obtained high-quality total
RNA from 42 bone marrow samples from pediatric B-
ALL patients and four bone marrows from healthy
donors. Chromosomal abnormalities were assessed by a
combination of karyotype analysis and gene fusion-
specific polymerase chain reaction (PCR). LncRNA and
messenger RNA (mRNA) expression analyses were per-
formed using the LncPath™ Human Cancer Array
(Arraystar Inc.), which includes 2829 lncRNAs and 1906
protein-coding genes. Because lncRNA functions are
poorly defined, our pathway-focused approach allowed us
to predict lncRNA functions based on the function of
their associated mRNAs. A full description of our meth-
ods is included in the Supplementary Material. Our
microarray data has been uploaded to Gene Expression
Omnibus under the accession GSE128254.
Our pediatric B-ALL cohort included 24 ETV6-
RUNX1-positive patients and 18 ETV6-RUNX1-negative
patients (Supplementary Table S1). None of the ETV6-
RUNX1-negative patients had any other known chromo-
somal rearrangements (7 had normal karyotype, 8 were
hyperdiploid and 3 had unsuccessful karyotype analysis
but no gene fusions were identified by PCR). There were
no differences between the ETV6-RUNX1-positive and
the ETV6-RUNX1-negative subgroups regarding patient
sex, age, phenotype, central nervous system involvement,
percentage of blasts or risk group (Supplementary Table
S2). In addition, most patients were treated using similar
therapy protocols based on Spanish PETHEMA and
SEHOP protocols.
By performing an unsupervised hierarchical clustering
based on lncRNA expression profiles, all healthy samples
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clustered together and most ETV6-RUNX1-positive
samples were separated from most ETV6-RUNX1-
negative samples (Supplementary Fig. S1). To provide
insights into ETV6-RUNX1-specific lncRNA expression
signatures, we compared lncRNA expression in ETV6-
RUNX1-positive vs. ETV6-RUNX1-negative pediatric B-
ALL. We identified 117 differentially expressed lncRNAs
(Fig. 1a, b and Supplementary Table S3). The top upre-
gulated lncRNA in the ETV6-RUNX1-positive subgroup
was TCL6 (~3.8-fold) and the top down-regulated
Fig. 1 Differential expression of lncRNAs in ETV6-RUNX1-positive pediatric B-ALL vs. ETV6-RUNX1-negative pediatric B-ALL. a Heatmap of
differentially expressed lncRNAs. On top of the heatmap, ETV6-RUNX1-negative B-ALL samples are labeled in blue and ETV6-RUNX1-positive B-ALL
samples are labeled in red. Clustering was performed based on the Spearman correlation coefficient. Our candidate lncRNA, TCL6, is highlighted in
bold. b Volcano plot of the differential expression results. The horizontal dashed line represents a threshold of FDR= 0.05. The vertical dashed line
represents the thresholds of fold change=−1.5 and fold change= 1.5. Red dots represent the statistically significant differentially expressed
lncRNAs. Our candidate lncRNA, TCL6, is highlighted in bold. c Correlation of the expression of lncRNA/mRNA pairs in pediatric B-ALL datasets. We
focused our analysis on the unique lncRNA/mRNA pairs that were differentially expressed in our microarray data. For each pair, the Spearman
correlation coefficient between the normalized expression of the lncRNA and the normalized expression of the associated mRNA was assessed in our
data, as well as in external datasets of B-ALL patients and cell lines. Larger dots represent lower FDR-adjusted p-values. Our candidate lncRNA/mRNA
pair, TCL6/TCL1B, is highlighted in bold. The sample sizes were: n= 46 for our data, n= 80 for Lee et al.8, n= 64 for Ghazavi et al.5 and n= 44 for
Fernando et al.6. In addition, we analyzed data from 13 B-ALL cell lines from the Cancer Cell Line Encyclopedia (CCLE). Missing values are represented
with an “NA” mark.
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lncRNA was CCDC26 (~5.6-fold). Furthermore, we found
no significant enrichment of differentially expressed
lncRNAs or mRNAs from chromosomes 12 or 21, sug-
gesting that the t(12;21) translocation affects gene
expression at a genome-wide level. Using a Gene Ontol-
ogy Analysis, we identified overrepresented cancer-related
pathways among the differentially expressed lncRNAs/
mRNAs in the ETV6-RUNX1-positive vs. ETV6-RUNX1-
negative comparison (Supplementary Fig. S2 and Sup-
plementary Table S4).
Based on our predicted lncRNA/mRNA associations, we
identified 19 pairs of lncRNA/mRNA probes that were
differentially expressed between ETV6-RUNX1-positive and
ETV6-RUNX1-negative pediatric B-ALL (Supplementary
Fig. 2 Validation of the relevance of TCL6/TCL1B in pediatric B-ALL. a Correlation analysis of TCL6/TCL1B in independent datasets of pediatric B-
ALL patients. The points are colored according to the genomic aberration of the samples. The p-values were adjusted using the Benjamini–Hochberg
method. Sample sizes: n= 46 for our data, n= 80 for Lee et al.8, n= 64 for Ghazavi et al.5, n= 44 for Fernando et al (2015). b. Correlation analysis of
TCL6/TCL1B in the Cancer Cell Line Encyclopedia (CCLE), n= 13. The points are colored according to the genomic aberration of the samples.
c. Validation of the differential expression of TCL6 and TCL1B in three independent external B-ALL cohorts. Sample sizes: n= 46 for our data, n= 80
for Lee et al (2015), n= 64 for Ghazavi et al (2016) and n= 44 for Fernando et al.6. Kruskal–Wallis FDR-adjusted p-values are shown. d Kaplan–Meier
curve of pediatric B-ALL patients divided in two groups: “TCL6 high” and “TCL6 low”, based on whether TCL6 expression was above or beyond the
median. The logrank p-value is shown.
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Fig. S3 and Supplementary Table S5). The top differentially
expressed lncRNA/mRNA pair was TCL6/TCL1B. As a clue
for putative co-regulation, we assessed the correlation of the
expression of the lncRNA/mRNA pairs in our dataset as
well as in three independent external microarray studies in
pediatric B-ALL patients5,6,8 (combined n= 234; see Sup-
plementary Table S6 for details on sample sizes) and in the
Cancer Cell Line Encyclopedia. Only two lncRNA/mRNA
pairs, TCL6/TCL1B and RP11-69I8.3/CTGF, were con-
sistently correlated across all analyzed datasets (Figs. 1c, 2a,
b). Based on genomic information, TCL6 and TCL1B are
likely to originate from different regulatory elements (Sup-
plementary Note). Taken together, these results led us to
further investigate TCL6/TCL1B.
We confirmed the differential expression of TCL6/
TCL1B in a subset of our cohort using quantitative RT-
PCR (Supplementary Fig. S4). In addition, we further
validated the differential expression of TCL6/TCL1B
among pediatric B-ALL subgroups using external data5,6,8.
Both TCL6 and TCL1B were significantly upregulated in
ETV6-RUNX1-positive pediatric B-ALL compared to
hyperdiploid B-ALL, B-ALL with normal karyotype, and
B-ALL bearing any translocation but TCF3-PBX1 (Fig. 2c
and Supplementary Table S7). These results show that
high TCL6 and TCL1B expression levels are strongly
associated with ETV6-RUNX1-positive B-ALL.
Finally, we studied whether TCL6 or TCL1B expression
could predict patient survival. We observed a statistically
significant decrease in disease-free survival in “TCL6 low”
patients when compared to “TCL6 high” (logrank p=
0.025, Fig. 2d), but we did not observe this trend for
TCL1B. Remarkably, all four events (two deaths and two
relapses) affected “TCL6 low” patients. The two relapses
affected ETV6-RUNX1-positive patients and the two
deaths affected ETV6-RUNX1-negative patients. Inter-
estingly, the patients who relapsed (ALL35 and ALL36)
had the second and fourth lowest TCL6 expression levels
within the ETV6-RUNX1-positive subgroup. To validate
our results, we found no external pediatric B-ALL datasets
containing survival information and lncRNA expression.
However, using Prognoscan9, we found that high TCL6
expression associates with better patient prognosis in
multiple myeloma (GEO dataset GSE2658) and in one out
of four acute myeloid leukemia datasets (GSE12417).
Future research using larger patient cohorts should con-
firm the role of TCL6 in pediatric B-ALL and its useful-
ness as a prognostic biomarker.
TCL6 is thought to be involved in leukemogenesis, as
well as in mature B-cell neoplasms, but it has never been
shown to affect patient survival10,11. Although the mole-
cular function of TCL6 in cancer is unknown, it may
modulate the EGFR/AKT pathway at least in placental
tissue12. Here, we have predicted a functional relationship
between TCL6 and its neighboring protein-coding gene,
TCL1B. TCL1B is a co-activator of the protein kinase
AKT1 in T-cell leukemias and it has oncogenic activity
in vivo13,14. According to our results, TCL6 and TCL1B
are highly associated with ETV6-RUNX1-positive pedia-
tric B-ALL, in which the AKT pathway plays a major
role15. Based on this information, we propose a functional
link between TCL6, TCL1B and the AKT1 pathway, but
further research should be performed to confirm this
hypothesis.
In conclusion, we have identified TCL6 as a novel
lncRNA strongly related to ETV6-RUNX1-positive
pediatric B-ALL. We suggest that low TCL6 levels may
be associated with poor disease-free survival, even within
ETV6-RUNX1-positive B-ALL. LncRNA expression ana-
lysis could complement current cytogenetic and mole-
cular biological analyses applied in the routine diagnosis
of pediatric B-ALL to allow a better stratification of a
larger number of patients into risk-based treatment
groups.
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